Arterial Phase MRI Research Articles

Detection of arterial phase hyperenhancement of small hepatocellular carcinoma with MRI: Comparison between single arterial and multi-arterial phases and between extracellular and hepatospecific contrast agents

PurposeThe purpose of this study was to compare the detection rate of arterial phase hyperenhancement (APHE) in small hepatocellular carcinoma (HCC) between single arterial phase (single-AP) and triple hepatic arterial (triple-AP) phase MRI and between extracellular (ECA) and hepato-specific (HBA) contrast agents. Materials and methodsA total of 109 cirrhotic patients with 136 HCCs from seven centers were included. There were 93 men and 16 women, with a mean age of 64.0 ± 8.9 (standard deviation) years (range: 42–82 years). Each patient underwent both ECA-MRI and HBA (gadoxetic acid)-MRI examination within one month of each other. Each MRI examination was retrospectively reviewed by two readers blinded to the second MRI examination. The sensitivities of triple- and single-AP for the detection of APHE were compared, and each phase of the triple-AP sequence was compared with the other two. ResultsNo differences in APHE detection were found between single-AP (97.2%; 69/71) and triple-AP (98.5%; 64/65) (P > 0.99) at ECA-MRI. No differences in APHE detection were found between single-AP (93%; 66/71) and triple-AP (100%; 65/65) at HBA-MRI (P = 0.12). Patient age, size of the nodules, use of automatic triggering, type of contrast agent, and type of sequence were not significantly associated with APHE detection. The reader was the single variable significantly associated with APHE detection. For triple-AP, best APHE detection rate was found for early and middle-AP images compared to late-AP images (P = 0.001 and P = 0.003). All APHEs were detected with the combination of early-AP and middle-AP images, except one that was detected on late-AP images by one reader. ConclusionOur study suggests that both single- and triple-AP can be used in liver MRI for the detection of small HCC especially when using ECA. Early AP and middle-AP are the most efficient phases and should be preferred for detecting APHE, regardless of the contrast agent used.

Reliable prediction of survival in advanced-stage hepatocellular carcinoma treated with sorafenib: comparing 1D and 3D quantitative tumor response criteria on MRI.

To compare 1D and 3D quantitative tumor response criteria applied to DCE-MRI in patients with advanced-stage HCC undergoing sorafenib therapy to predict overall survival (OS) early during treatment. This retrospective analysis included 29 patients with advanced-stage HCC who received sorafenib for at least 60days. All patients underwent baseline and follow-up DCE-MRI at 81.5 ± 29.3days (range 35-140days). Response to sorafenib was assessed in 46 target lesions using 1D criteria RECIST1.1 and mRECIST. In addition, a segmentation-based 3D quantification of absolute enhancing lesion volume (vqEASL) was performed on the arterial phase MRI, and the enhancement fraction of total tumor volume (%qEASL) was calculated. Accordingly, patients were stratified into groups of disease control (DC) and disease progression (DP). OS was evaluated using Kaplan-Meier curves with log-rank test and Cox proportional hazards regression model. The Kaplan-Meier analysis revealed that stratification of patients in DC vs. DP according to mRECIST (p = 0.0371) and vqEASL (p = 0.0118) successfully captured response and stratified OS, while stratification according to RECIST and %qEASL did not correlate with OS (p = 0.6273 and p = 0.7474, respectively). Multivariable Cox regression identified tumor progression according to mRECIST and qEASL as independent risk factors of decreased OS (p = 0.039 and p = 0.006, respectively). The study identified enhancement-based vqEASL and mRECIST as reliable predictors of patient survival early after initiation of treatment with sorafenib. This data provides evidence for potential advantages 3D quantitative, enhancement-based tumor response analysis over conventional techniques regarding early identification of treatment success or failure. • Tumor response criteria on MRI can be used to predict survival benefit of sorafenib therapy in patients with advanced HCC. • Stratification into DC and DP using mRECIST and vqEASL significantly correlates with OS (p = 0.0371 and p = 0.0118, respectively) early after initiation of sorafenib, while stratification according to RECIST and %qEASL did not correlate with OS (p = 0.6273 and p = 0.7474, respectively). • mRECIST (HR = 0.325, p = 0.039. 95%CI 0.112-0.946) and qEASL (HR = 0.183, p = 0.006, 95%CI 0.055-0.613) are independent prognostic factors of survival in HCC patients undergoing sorafenib therapy.

Improved Display of Hepatic Arterial Anatomy Using Differential Subsampling With Cartesian Ordering (DISCO) With Gadoxetic Acid-Enhanced MRI: Comparison With Single Arterial Phase MRI and Computed Tomographic Angiography.

In clinical practice arterial anatomy evaluation is often determined using computed tomographic angiography (CTA); the effect of enhanced MRI has been neglected. To evaluate whether multiple arterial phase (MAP) images from patients who underwent differential subsampling with Cartesian ordering (DISCO) acquisition would improve the hepatic arterial display compared with single arterial phase (SAP) and CTA. A prospective, randomized trial. In all, 130 patients (mean age, 55.81 ± 9.43 years; range, 35-78 years) including 89 men and 41 women. 3.0T, DISCO, liver acquisition with volume acceleration-flexible (LAVA-Flex), CTA. A simple randomization was conducted and the study was subdivided into study part I (DISCO vs. SAP) and study part II (DISCO vs. CTA). Ten hepatic arterial segments were independently evaluated by three readers in the axial plane and the quality of hepatic arterial display was assessed using a four-point scale. Kendall's W-test, χ2 test, Mann-Whitney U-test, and Kruskal-Wallis one-way analysis of variance (ANOVA) test. Excellent interobserver agreement was obtained for hepatic arterial display (all Kendall's W values >0.80). For study part I, the mean arterial display scores for the common hepatic artery (CHA), proper hepatic artery (PHA), left hepatic artery (LHA), right hepatic artery (RHA), left gastric artery (LGA), and gastroduodenal artery (GDA) obtained with DISCO were higher than that obtained with SAP imaging (all P < 0.01). For study part II, comparable image quality for CHA (P = 0.798), PHA (P = 0.440), LHA (P = 0.211), RHA (P = 0.775) LGA (P = 0.468), and GDA (P = 0.801) was obtained with DISCO and CTA. The use of MAP acquisition with DISCO is superior to the use of SAP in hepatic arterial display and compares favorably with CTA; in the future, DISCO possibly can replace the latter ionization-related method to provide a more comprehensive evaluation of the liver arterial vessels. 1 Technical Efficacy Stage: 1 J. Magn. Reson. Imaging 2020;51:1766-1776.

Effect of Gadoxetic Acid Injection Duration on Tumor Enhancement in Arterial Phase Liver MRI

Rapid injection of gadoxetic acid has been shown not to increase tumor enhancement in arterial phase liver MRI for unknown reasons. This study aimed to investigate the effect of injection durations on peak contrast concentration in tumors and to correlate it with signal enhancement in gadoxetic acid-enhanced arterial phase MRI. Gadoxetic acid-enhanced arterial phase MRI was obtained using a bolus-tracking technique with injection durations of 1, 3, and 6s in six rabbits with VX2 liver tumors. The peak concentration of gadoxetic acid in the aorta and tumor was estimated by iopromide-enhanced time-resolved CT using the same injection volume and durations with those for MRI. Signal enhancement on MRI and peak enhancement on CT were compared and correlated. There was no significant difference in MR signal enhancement of tumors among the 3 injection durations (p = 0.87). In CT, shorter injection durations significantly increased peak contrast concentration in the aorta (p < 0.01) but produced equivalent peak contrast concentration in tumors (p = 0.24). The longer injections resulted in the stronger correlation between peak contrast concentration in CT and MR signal enhancement in tumors (r = 0.31, 0.43, and 0.86 with 1s-, 3s-, and 6s-injection, respectively) with a statistical significance only found with 6s-injection (p = 0.03). Estimation of contrast concentration by CT demonstrated that shorter injections did not increase peak contrast concentration in tumors despite increased peak concentration in the aorta. Furthermore, tumor signal enhancement in gadoxetic acid-enhanced arterial phase MRI was less correlated with the peak contrast concentration with shorter injections.

Gadoxetate disodium-related event during image acquisition: a prospective multi-institutional study for better MR practice.

To acknowledge the facts of gadoxetate disodium-related events in Japan and to achieve better MR practice by analyzing large cohort data with various MR parameters. This prospective multi-institutional study included 1993 patients (1201 men, mean age 66.4 ± 12.8years), who received dynamic MRI with gadoxetate disodium (gadoxetate group, n = 1646) or extracellular gadolinium-based contrast agents (other-GBCAs group, n = 347) between January and November 2016. Recorded data covered adverse reactions including dyspnea, breath-hold failure during acquisition, respiratory artifacts rated with a four-point scale, and MR parameters. We compared data between the two groups in whole cohort and age-, gender-, and institution-matched subcohort using χ2 test (n = 640). Logistic regression model was used to reveal independent associates of substantial artifacts in arterial phase imaging. Transient dyspnea rarely occurred in gadoxetate or other-GBCAs group (both < 1%). Gadoxetate group (vs other-GBCAs group) showed higher rates of breath-hold failure (whole cohort, 18.2% vs 7.7%, p < 0.001; subcohort, 17.6% vs 6.3%, p < 0.001) and substantial artifacts in arterial phase (7.2% vs 2.2%, p = 0.001; 7.4% vs 1.7%, p = 0.001). With single arterial phase protocol, substantial artifacts under gadoxetate were independently associated with age (odds ratio [OR] = 1.04, p < 0.001), hearing difficulty (OR = 2.92, p = 0.008), breath-hold practice required (OR = 1.61, p = 0.039), and short acquisition time (OR = 0.43, p = 0.005). Multiple arterial phase acquisition did not reduce the incident rate of substantial artifacts. Gadoxetate disodium was associated with breath-hold failure and substantial artifacts in arterial phase imaging, but not with dyspnea in Japan. Shorter acquisition time should be used to sustain image quality in gadoxetate disodium-enhanced arterial phase imaging. • Gadoxetate disodium administration leads to breath-hold failure and substantial imaging artifacts in arterial phase MRI in Japan. • Contrast agent-induced dyspnea in arterial phase and adverse reactions are rare in Japan, without showing differences between gadoxetate disodium or other extracellular gadolinium-based contrast agents. • Shorter acquisition time significantly reduces gadoxetate-induced imaging artifacts in the arterial phase.

Intrahepatic Mass-forming Cholangiocarcinoma: Arterial Enhancement Patterns at MRI and Prognosis.

Purpose To identify whether arterial enhancement pattern at MRI could predict the prognosis after surgical resection of intrahepatic mass-forming cholangiocarcinoma (IMCC). Materials and Methods Patients who underwent curative hepatic resection and preoperative MRI for IMCC from November 2007 to September 2016 were retrospectively evaluated. MRI enhancement pattern was classified by two radiologists. Recurrence and death data were retrieved until September 31, 2017. Prognostic factor analysis was performed by using preoperative and postoperative clinical-pathologic factors, as well as imaging findings. Results Data in 134 patients (median age, 63.0 years; 87 men and 47 women) were evaluated; median tumor size was 4.5 cm. Arterial phase MRI showed diffuse hypoenhancement in 33 patients, peripheral rim enhancement in 81 patients, and diffuse hyperenhancement in 20 patients. The 5-year risk of death in patients with IMCC with diffuse hyperenhancement was lower than that of patients with diffuse hypoenhancement or peripheral rim enhancement (5-year risk of death: 5.9% vs 87.9% vs 59.2%). Diffuse hypoenhancement (hazard ratio [HR], 41; 95% confidence interval [CI]: 5, 312; P < .01) and peripheral rim enhancement (HR, 11; 95% CI: 2, 85; P = .02) were associated with an increased risk of death compared with diffuse hyperenhancement. Patients with diffuse hyperenhancement of IMCCs had more frequent chronic liver disease (13 of 20; 65%), less frequent vascular invasion (six of 20; 30%), and less frequent tumor necrosis (three of 20; 15%) than other enhancement group (P < .05 for all). Conclusion The MRI arterial enhancement pattern was a prognostic marker in the preoperative evaluation of patients with resectable intrahepatic mass-forming cholangiocarcinoma. © RSNA, 2019 Online supplemental material is available for this article. See also the editorial by Yoon and Lee .

3:45 PM Abstract No. 376 Clear cell hepatocellular carcinoma is associated with non-viral cirrhosis and arterial-phase hypo-enhancement but does not predict outcome after locoregional therapy

Clear cell hepatocellular carcinoma (HCC) is a less common HCC cytologic variant associated with improved outcomes in studies prior to the advent of locoregional therapy (LRT). This study was undertaken to determine whether clear cell HCC predicts better outcomes after LRT. We retrospectively identified 124 consecutive patients (92 men, 32 women; median age 59 y) with 132 HCC (mean diameter 4.8 ± 3.9 cm) diagnosed by percutaneous biopsy between 2008-2017 prior to transarterial chemoembolization (TACE) (n = 51, 41%), yttrium-90 radioembolization (n = 17, 13%), percutaneous thermal ablation (n = 41, 33%), and combination TACE/ablation (n = 15, 12%). Baseline Barcelona Clinic Liver Cancer (BCLC) stage was 0/A (n = 48, 38%), B (n = 33, 26%), C (n = 27, 22%), and D (n = 16, 13%). Cytological subtype was determined from percutaneous core needle biopsy as 100% clear cells, focal clear cells, or no clear cells. Baseline clinical and imaging features, and radiologic response by mRECIST were correlated with cytological subtype using multinomial regression analysis. Time to progression (TTP) and transplant free survival (TFS) were analyzed by Cox proportional hazard models. Percutaneous core biopsies comprised entirely of clear cell subtype were associated with non-viral etiologies of HCC (OR 5.3 95% CI 1.64-17.16; p = 0.005), solid histological arrangement (OR 4.32 95% CI 1.14-16.37; p = 0.031), and hypo-enhancement on arterial phase CT or MRI images (OR 3.08 95% CI 1.02-9.3; p = 0.046). The clear cell subtype was not associated with improved objective response by mRECIST (OR 0.93 95% CI 0.37-2.33; p = 0.87), delayed TTP (HR 1.17 95% CI 0.86-1.6; p = 0.32), or better TFS (HR 1.01 95% CI 0.69-1.47; p = 0.96) in comparison to specimens with focal or no clear cells. There remained no significant association between the clear cell subtype and TTP or TFS after stratifying by LRT modalities. Clear cell HCC is more common in non-viral etiologies of cirrhosis and is associated with atypical enhancement on radiologic images. It does not, however, impart independent prognostic information prior to LRT.

4:21 PM Abstract No. 130 An automatic nonrigid co-registration algorithm for fusion of cone-beam computed tomography and magnetic resonance imaging: feasibility in Y90 radioembolization for hepatocellular carcinoma

Cone-beam CT (CBCT) during Y90 radioembolization (RE) of HCC allows precise selection of tumor-feeding arteries and improves accuracy of dose delivery. Co-registration with prior MRI provides additional guidance, particularly in poorly enhancing lesions. Clinically available rigid co-registration algorithms cannot account for anatomy deformations from respiratory motion and require manual interaction. Acceptable co-registration quality is unpredictable and user-dependent, limiting adoption of CBCT-MRI fusion into clinical practice. An automatic, non-rigid co-registration algorithm using the open source software packages ANTs, SLICER and Python was developed for fusion of preprocedural T1 late arterial phase MRI and CBCT acquired during the mapping phase of RE. Co-registration was performed in seven treatment-naive patients with ≤2 lesions measuring 2-10 cm. Clinically meaningful tumor and total liver volume overlays were assessed by two IR attending physicians on a nominal scale (0-5) and analyzed by the Wilcoxon test. Quantitative assessment of liver volume overlay by the non-rigid approach was performed using the dice similarity measure. Average scores for clinically meaningful overlay of target tumor(s) (4.3 vs. 4.3, p>0.99) and liver volumes (4.5 vs. 4.5, p>0.99) were identical for rigid and non-rigid algorithms. Dice similarity measure of liver volumes following non-rigid CBCT-MRI fusion was 0.88 ± 0.04. This is comparable to the best-reported measures in the literature for multi-modal, non-rigid liver co-registration. Clinically relevant CBCT-MRI fusion in HCC using an automatic, non-rigid co-registration algorithm from open source software is feasible. With further development, adoption of this approach may improve reliability and accuracy of image guidance for RE.

Dose-dependence of transient respiratory motion artifacts on gadoxetic acid-enhanced arterial phase MR images.

To compare the occurrence of transient respiratory motion (TM) artifacts between 0.05 mmol/kg and 0.025 mmol/kg gadoxetic-acid on arterial phase MRI intra-individually for evaluating dose-dependence of gadoxetic acid. This retrospective study involved 91 patients who underwent dynamic MRI at 1.5T at different times, one time with 0.05 mmol/kg and the other 0.025 mmol/kg gadoxetic-acid. Examinations with 0.05 mmol/kg totaled 91 scans, and examinations with 0.025 mmol/kg totaled 375 scans (due to multiple exams for several patients). The scan with 0.025 mmol/kg closest in time to the 0.05 mmol/kg scan was selected to minimize temporal effects. Two radiologists graded TM artifacts in the arterial phase images using a four-point scale: no, mild, moderate, and severe artifacts. Results were compared between the two protocols (0.05 mmol/kg versus all 0.025 mmol/kg and 0.05 mmol/kg versus selected 0.025 mmol/kg), and the odds ratio for moderate-to-severe artifacts was calculated. Significantly more TM artifacts were observed in the double dose (16/91 [17%]) scans compared with either all (17/375 [4%]; P < 0.01) or selected (3/91 [3%]; P = 0.01) standard dose scans. The odds ratio of the moderate-to-severe artifacts with the higher dose was 4.99-5.33. There appears to be dose-dependence of gadoxetic-acid and the occurrence of TM artifacts. 3 Technical Efficacy: Stage 3 J. Magn. Reson. Imaging 2018;47:433-438.

Multiple arterial phase MRI of arterial hypervascular hepatic lesions: improved arterial phase capture and lesion enhancement.

To establish if triple-phase arterial imaging improves the detection of arterial phase hyperintense lesions based on arterial phase capture, motion artifact degradation, and lesion enhancement when compared to single-phase imaging. Patients at risk for hepatocellular carcinoma were imaged at 3.0T. Seventy-three consecutive patients with a standard single-phase MRI and eighty-five consecutive patients were imaged using extracellular contrast with triple arterial phase MRI using three sequential accelerated acquisitions of 8s. Arterial phase capture and image quality were qualitatively categorized. Forty single-phase and forty-four triple-phase studies contained arterially enhancing lesions>1cm with washout appearance. The contrast-to-noise ratio (CNR) of the lesions was calculated. We compared the differences in means with Student t-tests and those in arterial phase capture with a Chi squared test with Yates correction. The triple-phase acquisitions captured the early or late arterial phases more frequently than did the single-phase acquisition (99% vs 86%; P value=0.006). Triple-phase also provided greater number of patients with early or late arterial phase imaging without motion artifact (92% vs 79%, P-value=0.05). The lesion analysis revealed increased maximum CNR in the triple-phase imaging (704.4) vs. single-phase imaging (517.2), P-value<0.001. Triple-phase acquisition provides more robust arterial phase imaging for hepatic lesions, with increased lesion CNR, compared to standard single-phase arterial phase imaging.

Transient respiratory motion artifact during arterial phase MRI with gadoxetate disodium: risk factor analyses.

The purpose of this article is to identify risk factors for arterial phase respiratory motion artifact in gadoxetate disodium-enhanced liver MRI. We retrospectively identified 220 consecutive patients who underwent 357 MRI examinations, including 68 patients who underwent multiple MRI examinations, with gadoxetate disodium between 2010 and 2013. The arterial phase timing was determined by a fluoroscopic-triggering method. T1-weighted unenhanced and contrast-enhanced images were reviewed to record respiratory motion artifact, which was graded on a 5-point scale. Arterial phase transient severe motion was considered to be present if the motion score was 4 or greater on the arterial phase images and if the motion scores were 2 or less on unenhanced and other contrast-enhanced images. Patient characteristics and risk factors (e.g., age, sex, weight, body mass index, medical and radiologic history, allergy to MRI and iodinated contrast agents, estimated glomerular filtration rate, Child-Pugh class, and findings on current MRI examinations) were recorded. We included a history of transient severe motion on prior MRI as a predictor variable. We performed univariable and multivariable analysis using the generalized estimated equations to adjust for clustering. The incidence of transient severe motion was 12.9% (46/357). On univariable analysis, a history of transient severe motion (odds ratio [OR] = 3.31; p = 0.04) on prior MRI and allergy to iodinated contrast agent (OR = 3.03; p = 0.01) statistically significantly increased the incidence of transient severe motion for a given MRI examination. These associations were not seen on multivariable analysis (adjusted OR = 2.38 and p = 0.23 for a history of transient severe motion; adjusted OR = 1.93 and p = 0.23 for allergy to CT contrast agent). The occurrence of transient severe motion during arterial phase MRI with gadoxetate disodium is 12.9% and is poorly predicted on the basis of risk factors.

Evaluation of Optimal Scan Delay for Gadoxetate Disodium–Enhanced Hepatic Arterial Phase MRI Using MR Fluoroscopic Triggering and Slow Injection Technique

The purpose of this article is to prospectively evaluate the optimal scan delay for gadoxetate disodium-enhanced hepatic arterial phase MRI of hypervascular hepatocellular carcinoma (HCC) using MR fluoroscopic triggering and a slow-injection technique. Sixty-three patients (37 men and 26 women; age range, 33-92 years; mean age, 68.2 years) underwent gadoxetate disodium-enhanced MRI; there were 33 hypervascular HCCs (size range, 8-57 mm; mean size, 19.8 mm) in 19 patients. The time from the start of contrast agent injection to its arrival in the abdominal aorta (time to arrival) and the time from contrast agent arrival to peak enhancement (time to peak) were determined using MR fluoroscopy using IV slow injection at 1 mL/s of contrast material and a saline chaser. All patients underwent four-phase whole-liver imaging with a 3D keyhole gradient-echo sequence during a single breath-hold immediately after confirmation of aortic peak enhancement. Delays from peak aortic enhancement to k-space filling were 5-9, 10-14, 15-19, and 20-28 seconds, respectively, in the four phases. Time to arrival, time to peak, and HCC-to-liver contrast were evaluated. The time to arrival (range, 11-24 seconds; mean, 16.2 seconds) and the time to peak (range, 3-10 seconds; mean, 6.8 seconds) showed considerable variation among patients. HCC-to-liver contrast peaked at the first phase in 58% of cases, at the second phase in 42% of cases, and at the third and fourth phases in 0% of cases. Mean HCC-to-liver contrast in the first and second phases was significantly higher than that in the third and fourth phases (p<0.01). Optimal scan delays for imaging hypervascular HCCs with gadoxetate disodium-enhanced hepatic arterial phase MRI was 7-12 seconds after the peak aortic enhancement using a slow-injection protocol.

Improved hepatic arterial phase MRI with 3‐second temporal resolution

To assess 3-s temporal resolution for arterial phase bolus timing on dynamic liver MRI. One hundred consecutive patients undergoing fluoro-triggered dynamic gadoxetate enhanced liver MRI with standard Cartesian k-space LAVA (Liver Acquisition with Volume Acceleration) were compared with 61 consecutive patients imaged using spiral k-space LAVA reconstructed at 3-s temporal resolution with sliding window reconstruction. For qualitative analysis, bolus timing, hepatic artery branch order visualized, and overall image quality were evaluated. For quantitative analysis, contrast to noise ratio between aorta and liver parenchyma, aorta and portal vein, and signal intensity ratio between aorta and liver parenchyma were calculated. MR fluoroscopy triggered single phase standard LAVA produced optimal arterial phase timing in 35% patients, compared with 88% with Spiral LAVA (P < 0.0001). Spiral LAVA had superior bolus timing scoring 2.0, compared with 1.0 with standard LAVA (P < 0.0001). Overall image quality and hepatic artery branch order visualization scoring were superior on spiral LAVA, compared with standard LAVA (P < 0.001). The aorta to liver parenchyma signal intensity ratio was also superior on spiral LAVA, compared with standard LAVA (2.8 vs. 2.2; P < 0.001). Dynamic liver MRI bolus timing improves using 3-s temporal resolution.

Comparison of two different injection rates of gadoxetic acid for arterial phase MRI of the liver

To compare two different injection rates for gadoxetic acid-enhanced hepatic arterial phase images on hepatic dynamic MRI. Hepatic arterial phase images were obtained after an intravenous bolus injection of gadoxetic acid at a rate of 1 mL/second in 62 patients and 2 mL/second in 64 patients on a 3 Tesla MR scanner using a test-bolus injection method. The signal-to-noise ratios (SNR) of the liver, portal vein, hepatic vein, aorta, spleen and pancreas were measured. The contrast-to-noise ratio (CNR) of hypervascular hepatic tumors was calculated. Two radiologists independently scored items to evaluate image quality of hepatic arterial phase and detected hypervascular hepatocellular carcinoma (HCC). The SNR of the aorta on the arterial phase images was significantly higher in the 1 mL/second group (235.43 +/- 82.59) than in the 2 mL/second group (190.94 +/- 96.90, P < 0.05). The SNRs of the liver, spleen and pancreas, the CNRs of hypervascular hepatic tumors, the detection rate of hypervascular HCC and subjective ratings for the optimal arterial enhancement were comparable between the two groups. Injection rates of 2 mL/second and 1 mL/second provided comparable image qualities on arterial phase images of hepatic dynamic MRI using gadoxetic acid.

Recurrence-free Survival after Radiofrequency Ablation of Hepatocellular Carcinoma. A Registry Report of the Impact of Risk Factors on Outcome

Despite the high complete necrosis rate of radiofrequency ablation (RFA), tumor recurrence, either local tumor recurrence or new tumor formation, remains a significant problem. Purpose of this study is to evaluate the pattern and risk factors for intrahepatic recurrence after percutaneous RFA for hepatocellular carcinoma (HCC). We studied 40 patients with 48 HCCs (< or = 3.5 cm) who were treated with percutaneous RFA. The mean follow-up period was 24.1 +/- 15.7 months. We evaluated the cumulative disease-free survival of overall intrahepatic recurrence, local tumor progression (LTP) and intrahepatic distant recurrence (IDR). Thirty host, tumoral and therapeutic risk factors were reviewed for significant tie-in correlation with recurrence: age; gender; whether RFA was the initial treatment for HCC or not; severity of liver disease; cause of liver cirrhosis; contact of tumor to major hepatic vessels and liver capsule; degree of approximation of tumor to the liver hilum; ablation time; degree of benign pre-ablational enhancement; sufficient safety margin; tumor multinodularity; tumor histological differentiation; tumor segmental location; maximum tumor diameter; degree of tumor pre-ablational enhancement at arterial phase CT, MRI or CT-angiography; and laboratory markers pre- and post-ablation (AFP, PIVKA II, TP, AST, ALT, ALP and TB). The incidence of overall recurrence, LTP and IDR was 65, 23 and 52.5%, respectively. The cumulative disease-free survival rates were 54.6, 74.8 and 78.3% at 1 year, 27.3, 71.9 and 46.3% at 2 years and 20, 71.9 and 29.4 at 3 years, respectively. Univariate and multivariate analysis showed that the significant risk factors for LTP were: tumor size > or = 2.3 cm, insufficient safety margin, multinodular tumor, tumors located at segments 8 and 5, and patient's age > 65 years (P < 0.05). No significant risk factor relationship for IDR could be detected. Our results would have clinical implications for advance warning and appropriate management of patients scheduled for RFA. Patients at risk of LTP should be closely monitored in the first year. Furthermore, regular long-term surveillance is essential for early detection and eradication of IDR.

Double Hepatic Arterial Phase MRI of the Liver with Switching of Reversed Centric and Centric K-Space Reordering

The purpose of our study was to evaluate the clinical feasibility and usefulness of a 2D spoiled gradient-recalled echo MR sequence with serial switching of reversed centric and centric k-space reordering for high-spatial-resolution gadolinium-enhanced double hepatic arterial phase (HAP) MRI of the liver. MR images (frequency, 512; phase encoding without interpolation, 224; 6-mm thickness with 1-mm gap; 30 slices per 18 seconds) were obtained with multiphase imaging in which central k-space line data were filled 10, 21, 49, and 181 seconds after arrival of contrast medium in the abdominal aorta for the early HAP (reversed centric reordering, center of k-space lines acquired at end of acquisition), late HAP (centric reordering, center of k-space lines at beginning of acquisition), portal venous phase (centric reordering), and equilibrium phase (centric reordering), respectively, in 102 consecutive patients with suspected liver disease, including 48 untreated hepatocellular carcinomas (HCCs) in 35 patients. Images were quantitatively assessed for degree of contrast enhancement in the abdominal aorta, spleen, portal trunk, liver parenchyma, hepatic veins, and HCCs. Images were qualitatively assessed for the effectiveness of contrast enhancement in each phase and for degree of image degradation due to artifacts. Enhancement of the abdominal aorta peaked in the early HAP, of the portal trunk in the late HAP, and of the hepatic parenchyma and veins in the portal venous phase. Mean HCC-to-liver contrast peaked in the early HAP and turned to a negative value in the portal venous and equilibrium phases. Sufficient image quality was achieved in 99 (97%) of the patients. One of the other three patients had motion artifacts due to body motion, and the other two had unsatisfactory respiratory suspension. Scan timing for early and late HAP was optimal in 74 (73%) of the patients, for late HAP lagged in 20 (20%), for early HAP was premature in six (6%), and for early HAP lagged in five (5%) of the patients. We confirmed the feasibility and usefulness of a 2D gadolinium-enhanced double HAP spoiled gradient-recalled echo sequence incorporating serial switching of reversed centric and centric k-space reordering. This method has the potential for use in high-spatial-resolution double HAP MRI for the diagnosis of hypervascular HCC.

Triple Arterial Phase Dynamic MRI with Sensitivity Encoding for Hypervascular Hepatocellular Carcinoma: Comparison of the Diagnostic Accuracy Among the Early, Middle, Late, and Whole Triple Arterial Phase Imaging

We assessed and compared the diagnostic accuracy of the early, middle, late, and whole triple arterial phase MRI with sensitivity encoding (SENSE) for the detection of hypervascular hepatocellular carcinoma (HCC). Thirty-one patients with 102 HCCs underwent dynamic MRI with SENSE. The findings of CT examinations, combined with those of visceral angiography or histopathologic examination, were used as the gold standard. After acquisition of T1- and T2-weighted images, gadolinium-enhanced triple arterial, portal, and delayed phase images were obtained. Acquisition of the triple arterial phase imaging was started at the timing of peak aortic enhancement and completed within a single breath-hold. Acquisition time for each phase was 8.4 sec. Four image sets including the early, middle, late, and whole triple arterial phase imaging were interpreted separately by four observers. The mean values of area under alternative-free-response receiver operating characteristic (AFROC) curve and of sensitivity were compared among the four image sets. The mean values of area under AFROC curve were 0.52, 0.66, 0.53, and 0.68 and of sensitivity were 45%, 64%, 48%, and 65% for the image sets with the early, middle, late, and whole triple arterial phase imaging, respectively. Both mean values were significantly higher for the image sets with the middle and whole triple arterial phase imaging than for those with the early and late arterial phase imaging. The middle arterial phase imaging with k-space centered at 12.6 sec after the peak aortic enhancement was optimal for detecting HCC and showed diagnostic accuracy equivalent to that of the whole triple arterial phase imaging.